Dermata Therapeutics (DRMA) Fundamental Analysis: Revenue, Earnings & Valuation

3.41 / 10

Netural

DRMA's fundamental score is 3.4/10, indicating subpar standing. Key positives include an interest coverage ratio of 15.48 and strong YoY revenue growth (Total: 78.47%, Operating: 92.66%). However, drawbacks such as high days sales outstanding (72.55) and a high PB-ROE (4.32) temper the outlook. These factors collectively suggest a selective fundamental view.

Analysis Checks(8/10)

Revenue-MV

Value-0.26

Score3/3

Weight18.84%

1M Return10.54%

Total operating revenue (YoY growth rate %)

Value78.47

Score2/3

Weight1.61%

1M Return1.11%

Days sales outstanding

Value72.55

Score1/3

Weight-2.07%

1M Return-1.57%

Profit-MV

Value0.46

Score2/3

Weight15.02%

1M Return8.45%

Net income-Revenue

Value-0.17

Score2/3

Weight15.04%

1M Return8.45%

PB-ROE

Value4.32

Score1/3

Weight18.29%

1M Return9.57%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.48

Score2/3

Weight-1.50%

1M Return-1.11%

Operating revenue (YoY growth rate %)

Value92.66

Score2/3

Weight0.62%

1M Return0.43%

Asset-MV

Value-0.50

Score2/3

Weight19.37%

1M Return10.15%

Cash-MV

Value-0.07

Score2/3

Weight14.77%

1M Return8.41%

Is DRMA undervalued or overvalued?

DRMA scores 3.41/10 on fundamentals and holds a Fair valuation at present. Backed by its -206.36% ROE, 0.00% net margin, -0.50 P/E ratio, 1.31 P/B ratio, and 111.46% earnings growth, these metrics solidify its Netural investment rating.